Current Challenges in Stem Cell Transplantation in Myelofibrosis.

about

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury.Prefibrotic myelofibrosis: treatment algorithm 2018

P2860

Q52641887-94053FE0-B55F-43C5-8AF4-3CBD6A829314 Q58592871-77029D2E-1A83-434C-B155-E8060FF78102

P2860

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Item

http://www.wikidata.org/entity/Q38569146

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

@en

type

Item

label

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

@en

prefLabel

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

@en

P1476

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

@en

P2093

Nicolaus Kröger

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

Allogeneic bone marrow transplantation for primary myelofibrosis.

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o

P2888

s11899-015-0279-9

P304

344-350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-015-0279-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017632989

http://www.w3.org/2001/XMLSchema#string

P698

26285891

http://www.w3.org/2001/XMLSchema#string

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

about

P2860

P2860

Current Challenges in Stem Cell Transplantation in Myelofibrosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698